Clinical Trial Update: Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is planned to evaluate dapagliflozin for regulating immunological activity in membranous nephropathy; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerulonephritis
• Membranous Nephropathy

Drugs mentioned

• Dapagliflozin (Farxiga) (dapagliflozin)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Glomerulonephritis | Phase 2 | Status: NOT_YET_RECRUITING